Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Drospirenone

FDA-approved product (tablet, oral), marketed as Drospirenone, Slynd.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Drospirenone
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Progestogens
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against MRSA. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA55.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli30.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae31.8% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis25.5% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Drospirenone in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.6 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-9.4 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-9.8 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-9.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Drospirenone with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Prospective Multicenter Study on Patients'Satisfaction With Angeliq® Micro in Real Clinical Practice Conducted in Russia

    NCT03126773 · start 2017-05-02

    Registered record
    Registry ID
    NCT03126773
    Conditions
    Menopause
    Interventions
    BAY86-4891
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2017-05-02
    Completion
    2020-06-18
    Enrolment
    1,570

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMenopause
    InterventionBAY86-4891
    PhaseNot recorded
    Registry statusCompleted

  • E4/DRSP Ovarian Function Inhibition Study

    NCT03091595 · start 2017-02-07

    Registered record
    Registry ID
    NCT03091595
    Conditions
    Prevention of Pregnancy
    Interventions
    15 mg E4/3 mg DRSP; 20 mcg EE/3 mg DRSP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2017-02-07
    Completion
    2018-06-08
    Enrolment
    82

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPrevention of Pregnancy
    Intervention15 mg E4/3 mg DRSP; 20 mcg EE/3 mg DRSP
    PhasePhase 2
    Registry statusCompleted

  • Levonorgestrel-releasing Intrauterine System Versus a Low-dose Combined Oral Contraceptive for Management of Adenomyosis Uteri

    NCT03037944 · start 2016-03-01

    Registered record
    Registry ID
    NCT03037944
    Conditions
    Adenomyosis
    Interventions
    Yasmin; Metraplant-E
    Study type
    INTERVENTIONAL
    Phase
    Early phase 1
    Registry status
    Unknown
    Start
    2016-03-01
    Completion
    2018-12-01
    Enrolment
    32

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdenomyosis
    InterventionYasmin; Metraplant-E
    PhaseEarly phase 1
    Registry statusUnknown

  • The Safety and Pharmacokinetics of Primapur and Gonal-f

    NCT03857230 · start 2015-10-29

    Registered record
    Registry ID
    NCT03857230
    Conditions
    Area Under Curve; Pharmacokinetics; Absorption
    Interventions
    Follitropin alfa (Primapur); Follitropin alfa (Gonal-F)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-10-29
    Completion
    2016-05-10
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionArea Under Curve; Pharmacokinetics; Absorption
    InterventionFollitropin alfa (Primapur); Follitropin alfa (Gonal-F)
    PhasePhase 1
    Registry statusCompleted

  • Effect of Food on the Bioavailability of 15 mg Estetrol/3 mg Drospirenone Tablets in Healthy Female Volunteers

    NCT02852681 · start 2015-08

    Registered record
    Registry ID
    NCT02852681
    Conditions
    Contraception
    Interventions
    15 mg E4/3 mg DRSP
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-08
    Completion
    2016-04
    Enrolment
    28

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    Intervention15 mg E4/3 mg DRSP
    PhasePhase 1
    Registry statusCompleted

  • Combined Oral Contraceptives and Fluoxetine Versus Combined Oral Contraceptives in Severe Premenstrual Syndrome

    NCT02488538 · start 2015-07

    Registered record
    Registry ID
    NCT02488538
    Conditions
    Premenstrual Syndrome
    Interventions
    Combined oral contraceptives; Fluoxetine; Combined oral contraceptives placebo; Fluoxetine placebo; Daily record of severity of problems
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2015-07
    Completion
    Not recorded
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPremenstrual Syndrome
    InterventionCombined oral contraceptives; Fluoxetine; Combined oral contraceptives placebo; Fluoxetine placebo +1 more
    PhasePhase 3
    Registry statusUnknown

  • The Effect of Oral Contraceptive Pills On Eyes

    NCT02841202 · start 2014-01

    Registered record
    Registry ID
    NCT02841202
    Conditions
    Adverse Effect of Oral Contraceptives, Subsequent Encounter
    Interventions
    oral contraceptive pills
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2014-01
    Completion
    2016-07
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAdverse Effect of Oral Contraceptives, Subsequent Encounter
    Interventionoral contraceptive pills
    PhasePhase 4
    Registry statusCompleted

  • Study of Treatment With the Combination of Drospirenone Plus Ethinyl Estradiol Plus Levomefolate Calcium in Mexican Women Seeking Contraception

    NCT01902264 · start 2013-08

    Registered record
    Registry ID
    NCT01902264
    Conditions
    Contraception
    Interventions
    EE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2013-08
    Completion
    2015-02
    Enrolment
    34

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEE20/DRSP/L-5-MTHF (Beyaz, BAY98-7071)
    PhasePhase 3
    Registry statusCompleted

  • Comparative Study of BAY86-5300 With an Extended Flexible Regimen for Endometriosis

    NCT01697111 · start 2012-10

    Registered record
    Registry ID
    NCT01697111
    Conditions
    Endometriosis
    Interventions
    EE20/DRSP(BAY86-5300); Placebo; Dienogest
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-10
    Completion
    2014-12
    Enrolment
    312

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndometriosis
    InterventionEE20/DRSP(BAY86-5300); Placebo; Dienogest
    PhasePhase 3
    Registry statusCompleted

  • Assessment of Autonomic Tone in Normotensive Women Using Combined Hormonal Oral Contraceptive Containing Drospirenone

    NCT01590849 · start 2011-01

    Registered record
    Registry ID
    NCT01590849
    Conditions
    Contraceptive Affecting the Autonomic Nervous System; Contraceptive Affecting Blood Pressure
    Interventions
    Contraceptives, Oral, Combined (Yaz®)
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2011-01
    Completion
    Not recorded
    Enrolment
    69

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraceptive Affecting the Autonomic Nervous System; Contraceptive Affecting Blood Pressure
    InterventionContraceptives, Oral, Combined (Yaz®)
    PhasePhase 3
    Registry statusUnknown

  • Study to Investigate Compliance With the Oral Contraceptive SH T00186D in a Flexible Extended Regimen Supported by a Dispenser With a Reminder Function

    NCT01257984 · start 2010-12

    Registered record
    Registry ID
    NCT01257984
    Conditions
    Contraception
    Interventions
    BAY86-5300; BAY86-5300
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2010-12
    Completion
    2012-09
    Enrolment
    508

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionBAY86-5300; BAY86-5300
    PhasePhase 3
    Registry statusCompleted

  • A Study to Evaluate the Pharmacokinetics of an Oral Contraceptive When Co-administered With GSK2248761 in Healthy Adult Female Subjects.

    NCT01195974 · start 2010-09-14

    Registered record
    Registry ID
    NCT01195974
    Conditions
    Infection, Human Immunodeficiency Virus; HIV Infections
    Interventions
    YASMIN; GSK2248761; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Terminated
    Start
    2010-09-14
    Completion
    2011-02-09
    Enrolment
    13

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInfection, Human Immunodeficiency Virus; HIV Infections
    InterventionYASMIN; GSK2248761; Placebo
    PhasePhase 1
    Registry statusTerminated

  • Effect of Two Different Dosages of Ethinyl-estradiol in Association With Drospirenone in Women With Polycystic Ovary Syndrome.

    NCT01519401 · start 2010-02

    Registered record
    Registry ID
    NCT01519401
    Conditions
    Polycystic Ovary Syndrome; Estro-progestin Drugs
    Interventions
    3 mg drospirenone and 20 µg ethinyl-estradiol; 3 mg drospirenone and 30 µg ethinyl-estradiol
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2010-02
    Completion
    2011-07
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPolycystic Ovary Syndrome; Estro-progestin Drugs
    Intervention3 mg drospirenone and 20 µg ethinyl-estradiol; 3 mg drospirenone and 30 µg ethinyl-estradiol
    PhaseNot applicable
    Registry statusCompleted

  • Effects of Counseling on the Continuation Rates and Compliance for Newly Prescribed Oral Contraceptives (Yasmin® or Any Other Oral Contraceptives (OC)

    NCT00905684 · start 2009-06

    Registered record
    Registry ID
    NCT00905684
    Conditions
    Contraception
    Interventions
    EE30/DRSP (Yasmin, BAY86-5131); Any other OC
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2009-06
    Completion
    2011-12
    Enrolment
    5,446

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionContraception
    InterventionEE30/DRSP (Yasmin, BAY86-5131); Any other OC
    PhaseNot recorded
    Registry statusCompleted

  • Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne

    NCT00722761 · start 2009-04

    Registered record
    Registry ID
    NCT00722761
    Conditions
    Acne Vulgaris
    Interventions
    drospirenone and ethinyl estradiol; Placebo tablet
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2009-04
    Completion
    2012-04
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    Interventiondrospirenone and ethinyl estradiol; Placebo tablet
    PhasePhase 3
    Registry statusCompleted